ABBV News 53.66 06/13/2014 04:21:46 Abbvie Inc. Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 53.66 $ABBV

Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson...

Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free.

Bristol-Myers' RA Drug Orencia Encouraging - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 5:10PM CDT
Bristol-Myers' Orencia performed well in a phase IIIb study as a combination therapy.

Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs  in 2013. Big drug companies, such as AbbVie,  Johnson & Johnson  , and Amgen  , offer...

AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland
PR Newswire Europe - Wed Jun 11, 5:48AM CDT
-- EUR85 million investment creates greater manufacturing capacity to deliver new medicines for patients

AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
PR Newswire - Wed Jun 11, 1:00AM CDT
AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.

AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire Europe - Tue Jun 10, 11:46PM CDT
-- New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas

Will Merck's Bold Hepatitis C Play Pay Off?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck continues to show that it is serious...

Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 12:10PM CDT
Merck's (MRK) decision to acquire Idenix (IDIX) for $24.50 per share in cash will boost its hepatitis C virus (HCV) pipeline.

Up 58%: Should You Buy Achillion Pharmaceuticals Today?
Michael Douglass and Matt Trogdon, The Motley Fool - Motley Fool - Tue Jun 10, 10:09AM CDT
Investors in  Achillion Pharmaceuticals  got a double-whammy of good news over the last two days, with  Merck 's purchase of fellow hepatitis c biotech  Idenix  pumping shares up over 40%. And Achillion is up over 50% today on further good news --...

AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
PR Newswire - Tue Jun 10, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.

Here's Why Merck Paid Triple the Price for Idenix
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 09, 6:15PM CDT
U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average both rose 0.1%. The technology-heavy Nasdaq Composite Index gained 0.4%. ...

Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014
M2 - Mon Jun 09, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx5qq/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - UCB S.A. - Sandoz Inc. - Swedish Orphan Biovitrum AB - Biosidus S.A. - Genor BioPharma Co., Ltd. - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/zrx5qq/idiopathic

Achillion Pharma Might be Next Hep C Takeout Target
at The Street - Mon Jun 09, 8:22AM CDT
Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.

Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal
at The Street - Mon Jun 09, 7:27AM CDT
With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from...

The Repercussions of Medicare's New Hepatitis C Push
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Jun 08, 12:31PM CDT
This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk...

Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting.

ASCO 2014 Puts These Biotech Stocks in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jun 03, 10:10AM CDT
Companies like Amgen (AMGN), Gilead (GILD), Pharmacyclics (PCYC) were out in full force presenting data on their approved and experimental cancer drugs.

Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other...

AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Tue Jun 03, 7:30AM CDT
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 82

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 185

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 120

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 125

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading

Top 5 Most Recently Viewed Articles

Preliminary Ratings Issued by KBRA for Upstart Securitization Trust

Updated Category News Views 388

Preliminary Ratings by KBRA for Upstart Securitization Trust 2024-1 KBRA recently assigned preliminary ratings to the three classes of notes issued by Upstart Securitization Trust 2024-1, also known as UPST 2024-1. This securitization involves a notable value of $208.001 million, primarily revolving around unsecured consumer loans. Details of the Ratings The assigned...

Continue Reading
Alchemy Pay Expands With Mississippi License Milestone

Updated Category News Views 247

Alchemy Pay's Latest Regulatory Push Well, here's something to chew on—Alchemy Pay, that stalwart in the fiat-crypto payment arena, just nabbed a Money Transmitter License down in Mississippi. Good move, because this means they've got their hands now in 20 states across the U.S. Quite a feat for a company out of Hong Kong looking to make waves in the regulatory ocean....

Continue Reading
Optimi Health Steps Up with Microdose Psilocybin

Updated Category News Views 27

New Horizons in the World of Psychedelics Optimi Health has just dropped a noteworthy update, and it's not something to ignore if you're keeping an eye on the psychedelic sector. They're rolling out microdose psilocybin products — a move that’s poised to stir the waters in clinical research. With dosages standardized at 1mg and 2mg, Optimi is targeting the need for...

Continue Reading
PowerBank Corporation Sees Stock Surge After Funding News

Updated Category News Views 111

PowerBank Corporation Stock Surge PowerBank Corporation (NASDAQ: SUUN) experienced significant stock gains recently, particularly on Wednesday. This rise came after the company announced an initial payment of $4 million for its solar projects, including Elmira, Jordan Road 1, and Jordan Road 2. This financial boost has attracted investor interest and propelled the stock...

Continue Reading
Lazard's Q3 2026: Surging Revenue, Waning Net Income

Updated Category News Views 88

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Continue Reading